Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:NVO), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 44% bearish. Among these notable options, 2 are puts, totaling $97,500, and 7 are calls, amounting to $332,890.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $150.0 for Novo Nordisk during the past quarter.
Volume & Open Interest Development
In today's trading context, the average open interest for options of Novo Nordisk stands at 1988.56, with a total volume reaching 2,194.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $100.0 to $150.0, throughout the last 30 days.
Novo Nordisk Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|
NVO | CALL | SWEEP | BULLISH | 09/20/24 | $3.75 | $3.7 | $3.7 | $140.00 | $84.3K | 8.6K | 255 |
NVO | CALL | TRADE | BULLISH | 01/16/26 | $46.0 | $45.05 | $46.0 | $100.00 | $69.0K | 770 | 16 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $28.4 | $25.35 | $26.1 | $130.00 | $54.8K | 700 | 0 |
NVO | PUT | SWEEP | BEARISH | 08/23/24 | $1.08 | $0.77 | $1.08 | $132.00 | $54.0K | 552 | 500 |
NVO | PUT | TRADE | BULLISH | 12/20/24 | $14.75 | $14.5 | $14.5 | $145.00 | $43.5K | 106 | 30 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Novo Nordisk's Current Market Status
- Trading volume stands at 1,297,641, with NVO's price up by 2.03%, positioned at $137.15.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 77 days.
Professional Analyst Ratings for Novo Nordisk
In the last month, 2 experts released ratings on this stock with an average target price of $160.0.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160.
- Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Novo Nordisk with a target price of $160.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
財力雄厚的投資者對諾和諾德(紐約證券交易所代碼:NVO)採取了看漲態度,這是市場參與者不容忽視的。我們對本辛加公開期權記錄的追蹤今天揭示了這一重大舉措。這些投資者的身份仍然未知,但是NVO的如此實質性的變動通常表明重大事件即將發生。
我們今天從觀察中收集了這些信息,當時Benzinga的期權掃描儀重點介紹了諾和諾德的9項非同尋常的期權活動。這種活動水平與衆不同。
這些重量級投資者的總體情緒存在分歧,55%的人傾向於看漲,44%的人傾向於看跌。在這些值得注意的期權中,有兩個是看跌期權,總額爲97,500美元,7個是看漲期權,總額爲332,890美元。
預測的價格區間
分析這些合約的交易量和未平倉合約,看來大型企業一直在關注諾和諾德在過去一個季度的價格範圍從100.0美元到150.0美元不等。
交易量和未平倉合約的發展
在當今的交易背景下,諾和諾德期權的平均未平倉合約爲1988.56,總成交量達到2,194.00。隨附的圖表描繪了過去30天內Novo Nordisk高價值交易的看漲和看跌期權交易量以及未平倉合約的變化情況,行使價走勢從100.0美元到150.0美元不等。
Novo Nordisk 看漲和看跌交易量:30 天概述
值得注意的期權活動:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|
NVO | CALL | SWEEP | BULLISH | 09/20/24 | $3.75 | $3.7 | $3.7 | $140.00 | $84.3K | 8.6K | 255 |
NVO | CALL | TRADE | BULLISH | 01/16/26 | $46.0 | $45.05 | $46.0 | $100.00 | $69.0K | 770 | 16 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $28.4 | $25.35 | $26.1 | $130.00 | $54.8K | 700 | 0 |
NVO | PUT | SWEEP | BEARISH | 08/23/24 | $1.08 | $0.77 | $1.08 | $132.00 | $54.0K | 552 | 500 |
NVO | PUT | TRADE | BULLISH | 12/20/24 | $14.75 | $14.5 | $14.5 | $145.00 | $43.5K | | |
關於 Novo Nordisk
諾和諾德擁有全球品牌糖尿病治療市場約三分之一的份額,是全球領先的糖尿病護理產品提供商。該公司總部位於丹麥,生產和銷售各種人用和現代胰島素、注射型糖尿病治療藥物(如 GLP-1 療法)、口服抗糖尿病藥物和肥胖療法。Novo還有一個生物製藥板塊(約佔收入的10%),專門研究血友病和其他疾病的蛋白質療法。
在對圍繞Novo Nordisk的期權交易進行了全面審查之後,我們將對該公司進行更詳細的審查。這包括評估其當前的市場狀況和表現。
諾和諾德的當前市場狀況
諾和諾德的專業分析師評級
上個月,2位專家發佈了該股的評級,平均目標價爲160.0美元。
期權交易帶來更高的風險和潛在的回報。精明的交易者通過不斷自我教育、調整策略、監控多個指標以及密切關注市場走勢來管理這些風險。通過Benzinga Pro的實時提醒,隨時了解Novo Nordisk的最新期權交易。